1. News You Can Use… Josh Stewart, PharmD Candidate 2016 Pete Koval, PharmD Cone Health Family Medicine October 2015

2. Drug Approval Extension Spiriva (tiotropium) is now FDA- approved in asthma with Respimat Was previously only indicated for COPD Asthma dose: 2 inh once daily of 1.25mcg (1.25mcg x 2 inhalations) = total 2.5mcg COPD dose: 2.5mcg X 2 inh = total 5mcg 09/16/15 boehringer-ingelheim.com

3. New Drug Approval Veltassa (patiromer) gained FDA approval for hyperkalemia Not indicated for acute treatment Used for patients with chronic hyperkalemia on RAAS inhibitors 10/22/2015 FDA.gov

4. New Drug Approval The FDA has approved the use of Aristada (aripiprazole lauroxil) extended release injection to treat schizophrenia It is the 2 nd once-monthly aripiprazole injection approved by the FDA (Abilify Maintena) 10/06/2015 FDA.gov

5. New Drug Approval Dyanavel XR (amphetamine) has been approved by the FDA for the treatment of ADHD in children 6 years and older It is an oral suspension that contains both extended-release and immediate- release properties 10/20/2015 prenewswire.com

6. Generic Drug Availability Paliperidone (Invega) is now available as a generic formulation It is indicated for treatment of schizophrenia in patients 12 and older 9/29/2015 PharmacyTimes.com

7. P&T Committee Ivabradine (Corlanor®) is now on Cone Health’s formulary Indicated for reduction of hospitalizations in people with worsening heart failure who meet the following criteria : Stable symptomatic CHF with LVEF <35% In sinus rhythm with resting heart rate > 70 bpm On maximally tolerated beta blockers or have a contraindication to beta blocker use 10/21/15 Cone Health P & T

8. P&T Committee Rapivab (peramivir) will NOT be added to the Cone Health formulary Injectable antiviral for influenza Concerns: high cost, IV formulation, not approved for pediatric use 10/21/2015 Cone Health P & T

9. Trial Review Jardiance (empagliflozin) showed CV and mortality benefit in diabetic patients against placebo in a recent study Patients randomized to empagliflozin 10mg, 25mg, or placebo for >3 years Patients on empagliflozin showed a lower rate of cardiovascular events and death from any cause 9/17/2015 N Engl J Med